Lisata Therapeutics, Inc. (LSTA)

NASDAQ: LSTA · IEX Real-Time Price · USD
+0.01 (0.23%)
At close: Sep 30, 2022 4:00 PM
-0.02 (-0.45%)
After-hours: Sep 30, 2022 7:35 PM EDT
Market Cap 36.21M
Revenue (ttm) n/a
Net Income (ttm) -24.57M
Shares Out 7.82M
EPS (ttm) -6.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 106,893
Open 4.44
Previous Close 4.41
Day's Range 4.32 - 4.80
52-Week Range 4.23 - 18.60
Beta 0.91
Analysts n/a
Price Target 68.85 (+1,387.0%)
Earnings Date Nov 2, 2022

About LSTA

Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kid... [Read more...]

Industry Biotechnology
Founded 1980
CEO David Mazzo
Employees 27
Stock Exchange NASDAQ
Ticker Symbol LSTA
Full Company Profile

Financial Performance

Financial Statements


There is no news available yet.